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ABSTRACT: Chiral γ-aminobutyric acid (GABA) analogues represent abundantly
prescribed drugs, which are broadly applied as anticonvulsants, as antidepressants,
and for the treatment of neuropathic pain. Here we report a one-pot two-step
biocatalytic cascade route for synthesis of the pharmaceutically relevant enantiomers
of γ-nitrobutyric acids, starting from simple precursors (acetaldehyde and
nitroalkenes), using a tailor-made highly enantioselective artiﬁcial “Michaelase” (4-
oxalocrotonate tautomerase mutant L8Y/M45Y/F50A), an aldehyde dehydrogenase
with a broad non-natural substrate scope, and a cofactor recycling system. We also
report a three-step chemoenzymatic cascade route for the eﬃcient chemical reduction
of enzymatically prepared γ-nitrobutyric acids into GABA analogues in one pot,
achieving high enantiopurity (e.r. up to 99:1) and high overall yields (up to 70%).
This chemoenzymatic methodology oﬀers a step-economic alternative route to
important pharmaceutically active GABA analogues, and highlights the exciting
opportunities available for combining chemocatalysts, natural enzymes, and designed artiﬁcial biocatalysts in multistep
syntheses.
KEYWORDS: systems biocatalysis, cascades, “Michaelase”, γ-aminobutyric acids, γ-nitrobutyric acids, enzyme engineering,
pharmaceuticals
■ INTRODUCTION
Analogues of γ-aminobutyric acid (GABA, Figure 1) represent
abundantly prescribed drugs, which are broadly applied as
anticonvulsants, as antidepressants and for the treatment of
neuropathic pain. With an increasing world population and life
expectancy, the demand for GABA analogues is expected to
even further increase. The eﬃcient asymmetric synthesis of
pharmaceutically active GABA analogues has therefore
attracted enormous attention. With current synthesis routes
often involving kinetic resolutions,1−3 there is a need to
investigate alternative asymmetric synthesis routes that are
potentially greener, more sustainable, and more step-economic.
In this regard, the use of a systems (bio)catalysis approach4−8
in which diﬀerent catalysts are combined to construct reaction
cascades for eﬃcient synthesis of GABA analogues is an
attractive idea. This approach aims to minimize the number of
reaction steps and improve the “pot-economy” of the process.9
We envisioned that pharmaceutically active GABA ana-
logues, such as pregabalin, phenibut, baclofen, and ﬂuorophe-
nibut, could be prepared via one-pot three-step (chemo)-
enzymatic cascade reactions, using simple and inexpensive
starting materials and avoiding (de)protecting steps and
intermediate puriﬁcations (Figure 1). For establishing the
required C−C bond stereochemistry, the asymmetric Michael-
type addition of acetaldehyde (1) to nitroalkenes 2a−d is of
high interest. This would give convenient access to chiral γ-
nitroaldehydes 3a−d, which in two steps (oxidation of 3a−d
into 4a−d followed by reduction of 4a−d into 5a−d) can be
converted into the desired GABA analogues.
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The asymmetric Michael-type addition of 1 to 2a−d is
certainly not trivial. Multiple organocatalytic approaches to
obtain enantioenriched γ-nitroaldehydes have been reported,
mainly using small peptide- and proline-based organo-
catalysts.10−13 However, examples including acetaldehyde as
donor substrate are scarce and a high catalyst loading in
organic solvent is typically applied. Therefore, there is great
interest in the development of biocatalytic procedures for the
enantioselective synthesis of γ-nitroaldehydes. However,
enzymes that naturally catalyze these required carbon−carbon
bond-forming Michael-type additions are not known to be
present in nature. In fact, only a few enzymes are known to be
able to catalyze any type of C−C bond-forming Michael-type
addition.14,15 Interestingly, Hilvert and co-workers published
the elegant enzymatic synthesis of γ-nitroketones, but not γ-
nitroaldehydes, by both acetone addition to nitroalkenes and
nitroalkane addition to conjugated ketones using a highly
engineered computationally designed retroaldolase.16 We have
previously reported that 4-oxalocrotonate tautomerase (4-OT)
can promiscuously catalyze the addition of small aldehydes,
most notably the highly reactive acetaldehyde, to various
aliphatic and aromatic nitroalkenes.17−20 Analogous to proline-
based organocatalysts, the 4-OT enzyme utilizes an N-terminal
proline (Pro-1) as key catalytic residue in promiscuous aldol
condensations21,22 and Michael-type additions,19 most likely
via enamine catalysis.22,23 By using mutability-landscape
guided enzyme engineering,24 a mutant of 4-OT (4-OT
M45Y/F50A) was generated that showed inverted enantiose-
lectivity in acetaldehyde additions to nitroalkenes,25 allowing
the enzymatic synthesis of the pharmaceutically relevant
enantiomers of γ-nitroaldehydes 3a−d. However, the enantio-
selectivity of 4-OT M45Y/F50A is too low for biocatalytic
application, providing the desired γ-nitroaldehyde products
with only modest enantiomeric excess.25
Here, we report the development of a tailor-made artiﬁcial
“Michaelase”, which exhibits improved enantioselectivity,
activity and cosolvent stability compared to the parental
enzyme 4-OT M45Y/F50A, for additions of 1 to nitroalkenes
2a−d yielding γ-nitroaldehydes 3a−d with outstanding
enantiopurity. This artiﬁcial “Michaelase” was combined with
a natural aldehyde dehydrogenase and a cofactor recycling
NADH-oxidase to give a one-pot two-step reaction cascade for
the synthesis of γ-nitrobutyric acids 4a−d in high yields and
with excellent enantiomeric excess. Finally, the reaction
cascade was further extended by the inclusion of nickel boride,
promoting the conversion of enzymatically prepared 4a−d into
the desired GABA analogues 5a−d, which resulted in a one-
pot three-step chemoenzymatic reaction cascade (Figure 1A).
Given that all steps were performed under aqueous conditions
with high conversions, the desired GABA analogues 5a−d were
obtained in good isolated yields of up to 70% and with
excellent enantiomer ratio (e.r.) values of up to 99:1. This new
methodology oﬀers a step-economic alternative route to
important pharmaceutically active GABA analogues, and
highlights the exciting opportunities available for combining
chemocatalysts, natural enzymes, and designed artiﬁcial
biocatalysts in multistep syntheses of valuable chemical
products.
■ EXPERIMENTAL METHODS
Library Screening. After transformation with 4-OT I2X/
L8X/M45Y/F50A library DNA, individual E. coli BL21(DE3)
colonies were used to inoculate 2× 1.25 mL LB supplemented
with 100 μg/mL ampicillin and 100 μM isopropyl β-D-1-
thiogalactopyranoside (IPTG) in 96-deep well plates (Greiner
Bio-one, 96-well Masterblock). The plates were sealed with
sterile gas-permeable seals (Greiner Bio-one, BREATHseal)
and incubated at 37 °C, with overnight shaking at 250 rpm.
After the incubation, the plates were centrifuged (2232g, 8
min). The supernatant was discarded, and the individual
pellets were lysed by resuspension in 350 μL of BugBuster
(Novagen) supplemented with 25 U/mL benzonase (Nova-
gen). The lysis was continued for 20 min at room temperature
under vigorous shaking. The lysates were cleared by
centrifugation (2232g, 55 min, 4 °C) after which the Cell
Free Extract (CFE) was obtained. The ﬁnal reaction mixture
for monitoring the addition of 1 to 2a consisted of the
following: CFE (40% v/v), 150 mM 1, 5 mM 2a, DMSO (5%
v/v) in 20 mM sodium phosphate buﬀer pH 6.5, 500 μL ﬁnal
volume. The reactions were performed in 96-deep well plates
sealed by ultraviolet transparent plate seals (VIEWseal, Greiner
Bio-One) at room temperature. After 50 min the reaction was
stopped by extraction with 300 μL toluene, which caused the
proteins to precipitate. The organic layer was separated from
the water layer by centrifugation (2232g, 20 min). The plates
containing the water and organic layer were incubated at −80
°C for 30 min to freeze the water layer and hence preventing
Figure 1. Chemoenzymatic cascade synthesis of pharmaceutically active GABA analogues. (A) Envisioned (chemo)enzymatic cascade synthesis of
pharmaceutically active GABA analogues. Abbreviations: 4-OT*, newly engineered 4-OT variant that functions as a highly enantioselective artiﬁcial
“Michaelase”; ALDH, aldehyde dehydrogenase; NR, nitroreductase. (B) Structures of GABA and its analogues pregabalin, phenibut, baclofen, and
ﬂuorophenibut.
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accidental uptake of part of the water layer. An aliquot of 50
μL from the organic layer was transferred to a GC vial by a
robotic pipetting station. For analysis of the amount and
enantiopurity of the enzymatic product 3a, 8 μL of the organic
layer was injected on a gas chromatograph using an Astec
CHIRALDEX G-TA column, isocratic 125 °C (carrier gas He,
1.69 mL/min). Flame ionization detection; retention time S-
3a: 25.6 min, retention time R-3a 26.9 min. The assignment of
the absolute conﬁguration of product 3a was based on earlier
reported data.17,25
Semipreparative Scale Experiments. All semiprepar-
ative scale experiments were based on previously reported
reaction conditions.17,25 Instead of DMSO, ethanol was used as
a cosolvent, since the desired products 3a−d were obtained at
the highest enantiopurity using 4-OT L8Y/M45Y/F50A in
combination with ethanol as the cosolvent. For the enzymatic
synthesis of 3a, the reaction mixture consisted of the following:
5.0 mg 2a (3 mM), 6.5 mg 4-OT L8Y/M45Y/F50A (75 μM,
2.5 mol % compared to 2a), and 2.56 mL ethanol (20% v/v) in
20 mM sodium phosphate buﬀer pH 6.5 to a ﬁnal volume of
12.8 mL. The reaction was performed in a 25 mL Erlenmeyer
ﬂask sealed with a rubber stopper. The reaction was initiated
by the addition of 108 μL of 1 (150 mM) and incubated at
room temperature. At timely intervals, a sample was withdrawn
from the reaction mixture and the reaction progress was
monitored by following the depletion in absorbance at 249 nm
corresponding to the concentration of substrate 2a.17 After the
measurement, the sample was combined with the reaction
mixture. After 50 min the reaction was ﬁnished and the
reaction mixture was extracted 3× with 10 mL toluene. The
organic layers were combined, washed with brine, and dried
with anhydrous Na2SO4. The dried organic layer was
concentrated in vacuo, yielding product 3a without any further
puriﬁcation (4.2 mg, 63% isolated yield). The enantiopurity
and absolute conﬁguration was determined by GC with a chiral
stationary phase (see library screening).
For the enzymatic synthesis of 3b−d, the reaction mixture
consisted of the following: nitroalkene (17.9 mg of 2b, 2 mM;
14.3 mg of 2c, 1.3 mM; or 20.1 mg of 2d, 2 mM), 11.5 mg of
4-OT L8Y/M45Y/F50A (28 μM, 1.4 mol % compared to 2b
and 2d, 2.15 mol % compared to 2c), ethanol (12 mL, 20% (v/
v) for 2b and 2d and 18 mL, 30% (v/v) for 2c) in 20 mM
sodium phosphate buﬀer pH 6.5 to a ﬁnal volume of 60 mL.
The reaction was performed in a 100 mL Erlenmeyer ﬂask
sealed with a rubber stopper. The reaction was initiated by the
addition of 169 μL 1 (50 mM) and incubated at room
temperature. At timely intervals a sample was withdrawn from
the reaction mixture and the reaction progress was monitored
by following the depletion in absorbance (λmax of 2b and 2c at
320 nm, λmax of 2d at 322 nm). After the measurement, the
sample was combined with the reaction mixture. When the
reaction was ﬁnished, the reaction mixture was extracted with
3× 40 mL ethyl acetate. The organic layers were combined,
washed with brine and dried with anhydrous Na2SO4. The
dried organic layer was concentrated in vacuo, yielding 3b−d
without any further puriﬁcation (3b 20.1 mg, 87% yield; 3c
17.2 mg, 97% yield; and 3d 24.0 mg, 94% yield). The aldehyde
functionality of 3b and 3c was derivatized to a cyclic acetal
(see supporting methods). The enantiopurity of 3b−d was
determined by reverse phase HPLC using a chiralpak AD-RH
column (150 mm × 4.6 mm, Daicel) (MeCN/water 70:30 for
3b, MeCN/water 62:38 for 3c and MeCN/water 30:70 for 3d,
25 °C, 0.5 mL/min ﬂow rate). Detection at 220 nm, retention
time R-3b: 8.3 min, S-3b 10.8 min; R-3c: 29 min, S-3c 37 min;
R-3d: 39 min, and S-3d: 41 min. The absolute conﬁguration
was determined by literature comparison.17
Two-Step Enzymatic Cascade Synthesis. The reaction
mixture contained 2a (22 mg, 3 mM), 4-OT L8Y/M45Y/
F50A (5 mol % compared to 2a), 5 mL of ethanol (10% v/v)
in 0.1 M sodium phosphate buﬀer (pH 7.3) to a ﬁnal volume
of 50 mL. The reaction was initiated by the addition of 50 mM
of 1 (2.5 mL from a freshly prepared 1 M stock solution) and
the reaction mixture was incubated at room temperature. At
timely intervals, a sample was withdrawn from the reaction
mixture and the reaction progress was monitored by following
the depletion in absorbance at 249 nm corresponding to the
concentration of substrate 2a.17 After the measurement, the
sample was combined with the reaction mixture. After 20 min,
the reaction was ﬁnished (full conversion of 2a into 3a) and
then to this PRO-ALDH(003) (0.5 mg/mL), PRO-NOX(009)
(1 mg/mL), and NAD+ (8 mM) were added. We used this
stepwise cascade approach because PRO-ALDH(003) also
showed activity toward starting substrate 1. Favorably, the
enzyme showed ∼3-fold higher activity toward substrate 3a (at
3 mM) than toward 1 (at 50 mM). Using this methodology,
complete oxidation of 3a into 4a was achieved with the
formation of less than 10 mM acetate as byproduct from 1.
After the PRO-ALDH(003)-catalyzed oxidation reaction was
completed, the reaction was stopped by acidifying the reaction
mixture to pH 5. The reaction mixture was extracted with 3×
50 mL ethyl acetate. The organic layers were combined,
washed with brine, and dried with anhydrous Na2SO4. The
dried organic layer was concentrated in vacuo and the product
was puriﬁed by silica gel column chromatography (hexane/
ethyl acetate 4:1) to obtain 4a (18 mg, 64% yield). The acid
functionality of 4a was derivatized to the corresponding methyl
ester (see supporting methods). The same reaction procedures
were followed for the synthesis of 4b−d. The enantiopurity of
derivatized 4a was determined by GC using a chiral Astec
CHIRALDEX G-TA column, 100 to 140 °C at a rate of 4 °C/
min, then 140 to 160 °C at a rate of 2 °C/min and ﬁnally held
at 160 °C. Flame ionization detection, retention time R-4a: 16
min, S-4a: 17 min. The enantiopurity of derivatized 4b−d was
analyzed by reverse phase HPLC using a chiral column
(Chiralpak-ID, 150 mm × 4.6 mm, Daicel) (MeCN/water
30:70, 25 °C, 1 mL/min ﬂow rate). Detection at 210 nm,
retention time R-4b: 22.6 min, S-4b: 24.5 min; R-4c: 19.4 min,
S-4c: 24.4 min; R-4d: 23.5 min, S-4d: 26.6 min.
Three-Step Chemoenzymatic Cascade Synthesis. The
reaction mixture contained nitoalkene (3 mM of 2a and 4 mM
of 2b−d), 4-OT L8Y/M45Y/F50A (28−32 mg; 5 mol %
compared to 2a−d), and ethanol (10% v/v) in 0.1 M
NaH2PO4 buﬀer (pH 7.3) to a ﬁnal volume of 25 mL. The
reaction was initiated by the addition of 50 mM 1 (1.25 mL
from a freshly prepared 1 M stock solution in 0.1 M NaH2PO4
buﬀer pH 7.3) and the reaction mixture was incubated at room
temperature. At timely intervals, a sample was withdrawn from
the reaction mixture and the reaction progress was monitored
by following the depletion in absorbance corresponding to the
concentration of nitroalkene (see above). After the measure-
ment the sample was combined with the reaction mixture.
After the completion of the reaction, PRO-ALDH(003) (0.5
mg/mL), PRO-NOX(009) (1 mg/mL) and NAD+ (0.5 mM)
were added to the reaction mixture. After 30 min, the reaction
was quenched by acidifying the reaction mixture using 5 M
HCl until the pH dropped to 3. To this mixture, NiCl2·6H2O
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(40 mM) and NaBH4 (40 mM) were added at 0 °C, and
stirring was continued for 24 h at room temperature. The
reaction mixture was ﬁltered through a Celite pad and the
ﬁltrate concentrated in vacuo, after which the resulting
concentrated mixture was acidiﬁed to pH 3−4. The acidiﬁed
reaction mixture was loaded on a column packed with cation
exchange resin (5 g of Dowex 50WX8 hydrogen form). After
washing with deionized water (4 column volumes), the
product was eluted out with 0.5−1 M ammonia solution (4
column volumes). The ninhydrin-positive fractions were
collected, combined, and lyophilized to yield the desired
products 5a−d. Products 5a−d were derivatized to diaster-
eomers using sodium 2,4-dinitro-5-ﬂuorophenyl-L-valine amide
(see the Supporting Information) and their enantiopurity was
determined using reverse phase HPLC on a C18 column
(Kinetex 5u EVO C18 100A, 150 mm × 4.6 mm,
Phenomenex) at 25 °C (1 mL/min ﬂow rate). The mobile
phase was a 60:40 (v/v) mixture of aqueous buﬀer (0.2%
triethylamine, pH adjusted to 3.5 with dilute orthophosphoric
acid) and MeCN. Detection at 340 nm, retention time S-5a:
16.1 min, R-5a: 21.4 min; R-5b: 10.9 min, S-5b: 12.1 min; R-
5c: 17.2 min, S-5c: 20.2 min; R-5d: 12.3 min, S-5d: 13.6 min.
■ RESULTS
Eﬀect of Cosolvents on the Enzymatic Michael-Type
Addition Reaction. The previously reported 4-OT mutant
M45Y/F50A25 exhibits inverted enantioselectivity when
compared to wild-type 4-OT, allowing the enzymatic synthesis
of the pharmaceutically relevant enantiomers of γ-nitro-
aldehydes 3a−d (Figure 1). However, the enantioselectivity
of 4-OT M45Y/F50A is too low for biocatalytic application,
with for instance the production of 3a with an e.r. of 90:10 and
3c with an e.r. of only 62:38.25 To improve the
enantioselectivity of the 4-OT M45Y/F50A catalyzed
Michael-type additions, we initially focused our eﬀorts on
solvent engineering. Indeed, the use of diﬀerent solvent
systems has been reported to have a substantial eﬀect on the
enantioselectivity of diﬀerent enzyme catalyzed reactions.26,27
We selected the 4-OT catalyzed addition of 1 to 2a to test the
eﬀect of cosolvents on enantioselectivity, because the optical
purity of product 3a can be straightforwardly analyzed by gas
chromatography. Although the enzyme was still active at
concentrations of up to 40% (v/v) DMSO, increasing the
DMSO concentration had a detrimental eﬀect on the
enantioselectivity of the 4-OT M45Y/F50A-catalyzed reaction
(Figure 2). A similar loss of enantioselectivity was observed
when short-chain alcohols such as ethanol or methanol were
used as cosolvent. Notably, ethanol and methanol concen-
trations of >20% (v/v) led to enzyme precipitation, which
indicates a destabilizing eﬀect of the cosolvent on the
biocatalyst. Using aqueous solutions of glyceline and ethaline
(deep-eutectic solvents) led to inactivation of the enzyme at all
tested concentrations (10−60%, v/v). Diols, however, could be
used in high concentrations without observing inactivation and
with a positive eﬀect on the enantioselectivity (Figure 2). For
example, using up to 60% (v/v) ethylene glycol, 1,3-
propanediol or 1,4-butanediol did not aﬀect the enzymatic
activity and the e.r. of product 3a increased up to 95:5.
Engineering of a Highly Enantioselective Artiﬁcial
“Michaelase”. Although solvent engineering slightly im-
proved the enantioselectivity of the addition of 1 to 2a
catalyzed by 4-OT M45Y/F50A, at best a product e.r. of 95:5
was achieved. Therefore, protein engineering was required to
further enhance the enantioselectivity of this reaction. To
guide our engineering eﬀorts, we used the available crystal
structure of 4-OT M45Y/F50A in complex with nitrostyrene
2b (PDB: 5CLO).25 This structure suggests that the substrate
may bind in two distinct orientations relative to Pro-1, diﬀering
by a rotation of ∼180 deg around the longitudinal axis of the
substrate molecule. One substrate orientation is consistent
with the formation of the R enantiomer of the product,
whereas the other is consistent with formation of the S
enantiomer. We reasoned that by reducing the rotational
freedom of the substrate in the active site and/or repositioning
of Pro-1 relative to the substrate, the enantioselectivity of
M45Y/F50A may be improved. Therefore, we selected
position Leu-8, the side chain of which is involved in
formation of the binding pocket for the substrate’s R-group
(Figure 1), and position Ile-2, which is located next to Pro-1,
for site-saturation mutagenesis.28 Accordingly, a focused library
was constructed by randomizing positions Ile-2 and Leu-8
using NNK degeneracy, yielding library I2X/L8X/M45Y/
F50A. As the model reaction for activity and enantioselectivity
screening, the addition of 1 to 2a was chosen because the
quantity and optical purity of product 3a can be easily analyzed
by gas chromatography. We reasoned that if mutants
displaying enhanced activity and enantioselectivity were to
be found, then they could be tested for their ability to facilitate
the enantioselective addition of acetaldehyde to aromatic
nitroalkenes as well.
The library was transformed into Escherichia coli cells, and
screened by evaluating 960 transformants. This resulted in the
identiﬁcation of two quadruple mutants (I2W/L8Y/M45Y/
F50A and I2M/L8Y/M45Y/F50A) with signiﬁcantly improved
activity and enantioselectivity. These mutant enzymes were
puriﬁed to homogeneity and assayed for their ability to catalyze
the addition of 1 to 2a. Mutants I2W/L8Y/M45Y/F50A and
I2M/L8Y/M45Y/F50A both displayed excellent enantioselec-
tivity, providing product S-3a with an e.r. of 99:1 (Table S1),
and enhanced activity (4- and 5-fold, respectively) when
compared to that of M45Y/F50A (Figure 3a). Since both
quadruple mutants contain the L8Y mutation, the triple
mutant L8Y/M45Y/F50A was constructed to test the
Figure 2. Eﬀect of cosolvents on the enantioselectivity of the
enzymatic Michael-type addition reaction. Enantiopurity of 3a (as the
percentage of the S-enantiomer) in the 4-OT M45Y/F50A catalyzed
addition of 1 to 2a performed in the presence of increasing
concentrations of diﬀerent cosolvents.
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Figure 3. Progress curves of Michael-type additions catalyzed by diﬀerent 4-OT variants. (a) Addition of 1 (150 mM) to 2a (5 mM) in 20 mM
sodium phosphate buﬀer (pH 6.5) and 5% (v/v) DMSO. Diﬀerent 4-OT mutants were used as a catalyst at a concentration of 100 μM. YA: 4-OT
M45Y/F50A, FYA: 4-OT L8F/M45Y/F50A, WYYA: 4-OT I2W/L8Y/M45Y/F50A, MYYA: 4-OT I2M/L8Y/M45Y/F50A, YYA: 4-OT L8Y/
M45Y/F50A. (b) Addition of 1 (65 mM) to 2c (1.3 mM) in 20 mM sodium phosphate buﬀer (pH 6.5) and 45% (v/v) DMSO. Diﬀerent 4-OT
mutants were used as a catalyst at a concentration of 18 μM. YA: 4-OT M45Y/F50A, YYA: 4-OT L8Y/M45Y/F50A.
Table 1. 4-OT L8Y/M45Y/F50A Catalyzed Michael-Type Additions of 1 to 2a−d Yielding 3a−da
aAssay conditions: reaction mixtures consisted of 150 mM 1 (synthesis of 3a) or 50 mM 1 (synthesis of 3b−d), 3 mM 2a, 1.3 mM 2c or 2 mM 2b
and 2d in 20 mM sodium phosphate buﬀer, pH 6.5. The reaction volume was 12.8 mL (synthesis of 3a) or 60 mL (synthesis of 3b−d). 1.4 mol %
of 4-OT (compared to concentration nitroalkene) was used, except for entry 1 (2.5 mol %) and entry 3 (2.15 mol %). bFor 3a, the e.r. was
determined by GC with a chiral stationary phase. For 3b and 3c, the enzymatic product was ﬁrst converted into the corresponding ethylene glycol
acetal, of which the e.r. was determined by HPLC with a chiral stationary phase. For 3d, the e.r. was directly determined by HPLC with a chiral
stationary phase. The absolute conﬁguration was determined by comparison to literature data.17,25
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importance of the mutation at position Ile-2. In addition, the
triple mutant L8F/M45Y/F50A was constructed to test if a
structurally similar residue at position Leu-8 might result in
better catalytic properties. Interestingly, mutants L8Y/M45Y/
F50A and L8F/M45Y/F50A exhibited excellent enantioselec-
tivity in the addition reaction yielding S-3a with an e.r. of 99:1
(Table S1). To our delight, the catalytic activity of mutant
L8Y/M45Y/F50A for the addition of 1 to 2a was considerably
improved (6-fold) compared to that of the starting mutant
M45Y/F50A and higher than those of the quadruple mutants
I2M/L8Y/M45Y/F50A and I2W/L8Y/M45Y/F50A (Figure
3a). The activity of mutant L8F/M45Y/F50A was slightly
lower than that of L8Y/M45Y/F50A. Satisfyingly, mutant
L8Y/M45Y/F50A also displayed higher activity (3.5-fold) for
the addition of 1 to the aromatic nitroalkene 2c when
compared to that of mutant M45Y/F50A (Figure 3b).
Coincidentally, when compared to mutant M45Y/F50A,
mutant L8Y/M45Y/F50A also proved to be much more stable
in the presence of the desirable cosolvent ethanol, tolerating
concentrations of up to 30% (v/v) without losing activity or
enantioselectivity. In fact, the enantioselectivity of the 4-OT
L8Y/M45Y/F50A catalyzed addition of 1 to 2a in the presence
of 25% (v/v) ethanol was exceptional, yielding optically pure
S-3a (the pregabalin precursor) with an e.r. of >99:1 (Table
S1). On the other hand, mutant L8F/M45Y/F50A was rather
unstable in the presence of ethanol, with signiﬁcantly reduced
activity already at an ethanol concentration of 10% (v/v).
Because the L8Y/M45Y/F50A mutant showed the highest
catalytic activity and enantioselectivity, and because it tolerates
relatively high concentrations of the cosolvent ethanol without
loss of performance, it was selected for further study.
The synthetic usefulness of mutant L8Y/M45Y/F50A was
further investigated in semipreparative scale experiments with
nitroalkene acceptors 2a−d (Table 1). Ethanol was used as a
cosolvent in all reactions because in 20−30% (v/v) ethanol
excellent enantioselectivity was observed for the enzymatic
additions. Under optimized conditions, products 3a−d could
be synthesized with good isolated yields (63−97%) and
excellent enantioselectivity (e.r. up to >99:1). In all cases, the
pharmaceutically relevant enantiomer of the γ-nitroaldehyde
was synthesized [(S)-3a and (R)-3b−d]. These results
demonstrate the potential of this newly engineered artiﬁcial
“Michaelase”, which displays enhanced activity, improved
enantioselectivity and better ethanol stability compared to
the parent enzyme, for the asymmetric synthesis of optically
pure γ-nitroaldehydes, which are important precursors for the
valuable pharmaceuticals pregabalin, phenibut, baclofen and
ﬂuorophenibut.
Structural Basis for the Enhanced Enantioselectivity.
To obtain insight into how the active site of 4-OT L8Y/
M45Y/F50A is remodelled to facilitate the highly enantiose-
lective Michael-type addition reactions, we determined its
crystal structure at 1.9 Å resolution (Table S2). The overall
hexameric structure of 4-OT L8Y/M45Y/F50A is very similar
to that of wild-type 4-OT (PDB entry: 4X19)23 and of mutant
M45Y/F50A (PDB entry: 5CLN),25 with Cα-backbone root-
mean-square-deviations of 0.38 and 0.69 Å, respectively. A
more detailed structural comparison of 4-OT L8Y/M45Y/
F50A and the parental enzyme 4-OT M45Y/F50A with bound
nitrostyrene (PDB entry: 5CLO)25 shows that the extra
mutation (L8Y) in the triple mutant results in a slight shift of
residues 5−17, comprising the last residues of strand β1, the
following loop, and the N-terminal residues of helix α1
(maximum shift is 1.4 Å). In addition, residues 46−48
comprising the loop/310-helix after strand β2 show a maximum
shift of 2.2 Å. Residues Tyr-45 and Ala-50 line the active site
pocket, their side chains having a conformation very similar to
that observed in the M45Y/F50A mutant. Notably, two
conformations of Tyr-45 were observed. In one conformation,
the side chain of Tyr-45 is rotated toward the substrate binding
pocket. Overlaying this conformation with the structure of
M45Y/F50A in complex with nitrostyrene (2b) would result in
a clash between the aromatic ring of 2b and Tyr-45, suggesting
that this is not the active conformation. In the second
conformation, the side chain of Tyr-45 is ﬂipped to the back of
the active site, making H-bond interactions with His-6, similar
as is observed in the structure of M45Y/F50A.
Most importantly, at the interface of each dimer of the L8Y/
M45Y/F50A mutant, the Tyr-8 side chain lies “above” the
hydrophobic pocket that binds the aromatic ring of 2b in the
M45Y/F50A mutant (Figure 4a). While the pocket has
become narrower due to the extra L8Y mutation, the
Figure 4. Crystal structure of the newly engineered 4-OT L8Y/M45Y/F50A mutant. (a) Overlay of the crystal structures of mutant M45Y/F50A
with bound nitrostyrene (2b, in light gray color, PDB entry: 5CLO) and mutant L8Y/M45Y/F50A (in orange color, this work). The extra L8Y
mutation of the triple mutant has the tyrosine side chain lying above a hydrophobic pocket where nitrostyrene (2b) is bound in the double mutant,
close to the catalytic proline residue (Pro-1). (b) Close-up view at a similar orientation, with the surface representation of the L8Y/M45Y/F50A
mutant added, showing that nitrostyrene (2b) would snugly ﬁt in the hydrophobic pocket.
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comparison with the M45Y/F50A structure indicates that it
remains capable to accommodate 2b, with the aromatic rings
of Tyr-8 and the substrate forming a parallel displaced π−π
stacking interaction (Figure 4b). The narrower substrate
binding pocket is expected to be less tolerant toward
accommodating the alternate binding mode of 2b, which
would give the opposite enantiomer of the corresponding
product, because the substrate has little freedom to adjust its
conformation and orientation to minimize unfavorable close
contacts. These results indicate that the enhanced enantiose-
lectivity of the L8Y/M45Y/F50A mutant is not due to major
structural changes but is related to the replacement of Leu-8 by
a larger tyrosine residue, resulting in a narrower substrate
binding pocket that prevents the substrate to bind in two
distinct orientations relative to Pro-1. Thus, the reduction in
size of the substrate binding pocket explains the excellent
enantioselectivity of the 4-OT L8Y/M45Y/F50A mutant.
One-Pot Two-Step Enzymatic Cascade Synthesis of γ-
Nitrobutyric Acids. Having constructed an artiﬁcial “Michae-
lase” that is highly enantioselective for the addition of
acetaldehyde (1) to nitroalkenes 2a−d, yielding γ-nitro-
aldehydes (S)-3a and (R)-3b−d (Table 1), we focused our
Table 2. One-Pot Two-Step Biocatalytic Enantioselective Synthesis of γ-Nitrobutyric Acids 4a−da
aMichael-type addition of 1 to 2a−d catalyzed by 4-OT L8Y/M45Y/F50A or 4-OT A33D to form either S-3a and R-3b−d or R-3a and S-3b−d
respectively, followed by aldehyde oxidation catalyzed by PRO-ALDH(003), using PRO-NOX(009) for cofactor recycling, to form either S-4a and
R-4b−d or R-4a and S-4b−d. The reaction mixtures consisted of 50 mM 1, 3 mM 2a or 4 mM 2b−d in 100 mM sodium phosphate buﬀer pH 7.3
and 10% (v/v) ethanol. Five mol % of 4-OT (compared to concentration nitroalkene) was used, except for entry 6 (1.5 mol %) and entry 7 (3 mol
%). PRO-ALDH(003) was added to a ﬁnal concentration of 0.5 mg/mL, PRO-NOX(009) was added to a ﬁnal concentration of 1 mg/mL. The
concentration NAD+ was 8 mM (4a) or 10 mM (4b−d). The amounts of applied cofactor were adjusted such that short reaction times and high
conversions were achieved. bMonitored by UV spectroscopy. cMonitored by HPLC. dProducts 4a−d were esteriﬁed and the e.r. was determined by
GC or HPLC with a chiral stationary phase.
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attention on the development of a two-step enzymatic cascade
process for the synthesis of γ-nitrobutyric acids 4a−d, which
are more stable and practical GABA analogue precursors than
the corresponding γ-nitroaldehydes. The synthesis of these
compounds requires the coupling of the newly developed
“Michaelase” with an appropriate aldehyde oxidase or aldehyde
dehydrogenase (Table 2). Notably, using an oxidase would
result in the formation of hydrogen peroxide as a byproduct,
which could unfavorably react with the aldehyde substrates and
enzyme catalysts, necessitating an additional step for its
removal. Therefore, an aldehyde dehydrogenase with a broad
non-natural substrate scope, PRO-ALDH(003) available from
Prozomix Ltd., was used. Initial experiments showed that PRO-
ALDH(003) was dependent on either NAD+ or NADP+ and
could accept both (R)-3a and (S)-3a as substrates. For
cofactor regeneration, we used an NADH oxidase, PRO-
NOX(009) available from Prozomix Ltd., which converts
NADH to NAD+ using O2 and producing H2O. A water-
forming NOX enzyme is particularly suited to include in the
envisioned cascade synthesis, as it does not employ substrates
or generate products that complicate subsequent workup,
resulting in increased purity and yield of 4a−d. Using our
newly engineered artiﬁcial “Michaelase” 4-OT L8Y/M45Y/
F50A in combination with PRO-ALDH(003) and PRO-
NOX(009), we developed a one-pot two-step biocatalytic
cascade to synthesize the desired product (S)-4a in 64%
isolated yield and with an excellent e.r. of 99:1 (Table 2, entry
1). Using similar conditions, also (R)-4b−d could be
synthesized in good isolated yield (67−70%) and with
excellent e.r. values of up to 99:1 (Table 2, entries 2−4).
Interestingly, the modularity of this enzymatic cascade
approach and the ability of PRO-ALDH(003) to accept both
enantiomers of 3a−d as substrates, also allowed for the
synthesis of the opposite enantiomers of γ-nitrobutyric acids
4a−d. To this end, we replaced 4-OT L8Y/M45Y/F50A by
the previously engineered enantiocomplementary 4-OT variant
Table 3. One-Pot Three-Step Chemoenzymatic Cascade Synthesis of Pharmaceuticals 5a−da
aMichael-type addition of 1 to 2a−d catalyzed by 4-OT L8Y/M45Y/F50A to form S-3a and R-3b−d, followed by aldehyde oxidation catalyzed by
PRO-ALDH(003), using PRO-NOX(009) for cofactor recycling, to form S-4a and R-4b−d, followed by nitro reduction catalyzed by nickel boride
to form S-5a and R-5b−d. The reaction mixtures consisted of 50 mM 1, 3 mM 2a or 4 mM 2b−d in 100 mM sodium phosphate buﬀer pH 7.3 and
10% (v/v) ethanol. Five mol % of 4-OT (compared to concentration of nitroalkene) was used; PRO-ALDH(003) was added to a ﬁnal
concentration of 0.5 mg/mL; PRO-NOX(009) was added to a ﬁnal concentration of 1 mg/mL; 0.5 mM of NAD+ was added; 40 mM of NiCl2 and
40 mM of NaBH4 were used. Because of the poor stability of nickel boride in aqueous buﬀer, a 10-fold excess of this reagent (40 mM versus 3−4
mM 2a−d) is required to achieve high conversion. bMonitored by UV spectroscopy. cMonitored by HPLC. dMonitored by TLC. ePuriﬁed by
cation exchange chromatography. fProducts 5a−d were derivatized using Nα-(2,4-dinitro-5-ﬂuorophenyl)-L-valinamide, and the e.r. of the
corresponding diastereomers was determined by HPLC with an achiral stationary phase. Notably, the e.r. of product 5a is likely to be 99:1;
however, because a minor contaminant from the derivatizing agent has the same retention time as the R enantiomer of product 5a, the e.r. for
product 5a is cautiously reported as 98:2, consistent with the observed peaks in the HPLC chromatogram.
ACS Catalysis Research Article
DOI: 10.1021/acscatal.8b04299
ACS Catal. 2019, 9, 1503−1513
1510
A33D, which produces the opposite enantiomers of 3a−d.25
Under optimized conditions and using the appropriate
combination of enzymes in one pot, the desired products
(R)-4a and (S)-4b−d were obtained with excellent e.r. values
(99:1) and in 62−74% isolated yield (Table 2, entries 5−8).
One-Pot Three-Step Chemoenzymatic Cascade Syn-
thesis of γ-Aminobutyric Acids. Having developed a
modular one-pot two-step enzymatic cascade for the
production of both enantiomers of γ-nitrobutyric acids 4a−d,
we focused our attention on the extension of this cascade by
including a third step, converting 4a−d into the desired
pharmaceutically active γ-aminobutyric acids 5a−d. To the
best of our knowledge, no enzymes have been reported that
can catalyze the full reduction of aliphatic nitro groups, such as
those present in 4a−d, to the corresponding amines.29 While
several procedures for the chemical reduction of nitro groups
have been reported, most of these use organic solvents and are
not suitable to be executed in aqueous solutions. To prevent
the necessity of intermediate puriﬁcation of 4a−d, we selected
nickel boride as catalyst (NiCl2·6H2O in combination with
NaBH4), because this system has been reported to catalyze the
reduction of nitro groups in aqueous solutions.30,31 Pleasingly,
when using 10 equiv of nickel boride (NaBH4/NiCl2·6H2O),
the complete reduction of 4a−d into 5a−d in aqueous buﬀer
at pH 3 was achieved.
Having established that nickel boride can be used to set up a
three-step chemoenzymatic cascade reaction, 4-OT L8Y/
M45Y/F50A, PRO-ALDH(003), PRO-NOX(009), and
NaBH4/NiCl2·6H2O were combined in one pot. This
chemoenzymatic cascade proved to be eﬃcient, converting
the simple starting materials 1 and 2a into the desired product
(S)-5a with an isolated yield of 55% and an excellent e.r. of
98:2 (Table 3, entry 1). Similarly, this one-pot three-step
reaction cascade could also be used to eﬃciently synthesize
(R)-5b−d in good isolated yields (65−70%) and with excellent
e.r. values of 99:1 (Table 3, entries 2−4). Thus, access to the
pharmaceuticals pregabalin, phenibut, baclofen and ﬂuorophe-
nibut has been achieved using this newly developed one-pot,
three-step chemoenzymatic cascade process.
■ DISCUSSION
The use of diﬀerent enzymes to build reaction cascades for
eﬃcient synthesis of valuable chemical products is an emerging
concept in biocatalysis.4−7 This approach aims to minimize the
number of reaction steps, prevent the necessity of isolation of
intermediate products, and improve the “pot-economy” of the
process.9 Using such a systems biocatalysis strategy, we have
successfully demonstrated a one-pot two-step biocatalytic
cascade reaction for the synthesis of the pharmaceutically
relevant enantiomers of γ-nitrobutyric acids starting from
simple achiral precursors (acetaldehyde and nitroalkenes).
This synthetic route highlights a highly enantioselective
carbon−carbon bond-forming step catalyzed by a newly
engineered artiﬁcial “Michaelase”, 4-OT L8Y/M45Y/F50A,
which has no known biological counterpart. This tailor-made
enzyme shows non-natural substrate promiscuity, accepting
acetaldehyde for enantioselective addition to various nitro-
alkenes. The modularity of this two-step cascade reaction was
demonstrated by using a previously engineered enantiocom-
plementary 4-OT mutant, 4-OT A33D,25 to synthesize the
opposite enantiomers of the γ-nitrobutyric acids. We also
developed a three-step chemoenzymatic cascade route for the
conversion of enzymatically prepared γ-nitrobutyric acids by
chemical reduction into the corresponding γ-aminobutyric
acids in one pot. Given that the eﬃcient large-scale process for
the manufacture of pregabalin (5a) by Pﬁzer is based on a
lipase-catalyzed kinetic resolution with ex situ enantiomer
recycling,32 our one-pot asymmetric chemoenzymatic cascade
synthesis oﬀers an alternative route to pharmaceutically active
γ-aminobutyric acid products, as exempliﬁed by the enantio-
selective synthesis of pregabalin (3 steps, 55% yield), phenibut
(3 steps, 70% yield), baclofen (3 steps, 65% yield), and
ﬂuorophenibut (3 steps, 68% yield). This shows the exciting
opportunities available for combining chemocatalysts, natural
enzymes, and designed artiﬁcial biocatalysts in multistep
syntheses.5 It is anticipated that such a rapid synthesis strategy,
which avoids (de)protecting steps and intermediate puriﬁca-
tions, could be ﬂexibly extended to various other targets, for
example by using aldehyde donors with diﬀerent chain length
or by starting from structurally distinct nitroalkenes.
The key step of the developed cascade synthesis is the
enantioselective Michael addition of acetaldehyde to a
nitroalkene catalyzed by an engineered 4-OT variant (mutant
L8Y/M45Y/F50A). The development of this highly enantio-
selective 4-OT variant was achieved by using an engineering
strategy that involves simultaneous randomization at two sites
(Ile-2 and Leu-8, Figure 4) lining the substrate binding pocket
of 4-OT M45Y/F50A, a double mutant previously designed for
inverting the stereoselectivity to that required for GABA
precursor synthesis.25 The major beneﬁt of this structure-
guided engineering strategy lies in the reduction of the
sequence space that has to be covered in order to identify
valuable mutants.28 Screening of 960 transformants, which is
only a relatively small fraction of clones with respect to
statistical requirements for signiﬁcant coverage of possible
combinations in a double-site SSM library with NNK codons,
yielded two quadruple mutants (I2W/L8Y/M45Y/F50A and
I2M/L8Y/M45Y/F50A) with signiﬁcantly improved activity
and the desired high enantioselectivity. The best performing
triple mutant, L8Y/M45Y/F50A, was deductively constructed
from these quadruple mutants. Notably, this triple mutant
must have been included in the double-site SSM library, but
apparently was not identiﬁed due to insuﬃcient screening.
From this result it can be concluded that a single-site SSM
strategy at both positions would have been an even more
eﬃcient engineering strategy, with only the need for screening
of ∼200 transformants with acceptable statistical coverage of
possible mutants. In summary, we provide evidence that three
amino acid substitutions (L8Y/M45Y/F50A) are suﬃcient to
invert and dramatically enhance the enantioselectivity of 4-OT
for the Michael addition of acetaldehyde to various nitro-
alkenes.
A structural comparison of 4-OT M45Y/F50A complexed
with a nitroalkene substrate25 and unliganded 4-OT L8Y/
M45Y/F50A suggested that the new triple mutant has a
narrower binding pocket for the nitroalkene substrate (Figure
4). This reduction in size of the substrate binding pocket may
prevent the nitroalkene substrate to bind in two distinct
orientations relative to Pro-1, potentially explaining the
enhanced enantioselectivity. However, the possibility that the
observed nitroalkene substrate orientation is not relevant for
the catalytic bond-forming event cannot be excluded, because
the covalent enzyme-bound enamine intermediate, which is
formed between Pro-1 and acetaldehyde,23 may inﬂuence the
binding orientation of the nitroalkene substrate and the
trajectory of the nucleophilic addition.
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The currently employed amounts (1.4−5.0 mol %) of 4-OT
L8Y/M45Y/F50A are lower and reactions times of ≤30 min
are generally shorter than in the few conventional organo-
catalytic methodologies for identical type of Michael
reactions.12,33,34 Moreover, we take advantage of the water
solubility of the enzyme to achieve the reactions in
environmentally friendly aqueous buﬀer and not in organic
solvent. Nevertheless, the relatively high amounts of the 4-OT
L8Y/M45Y/F50A enzyme employed, required to ensure short
reaction times to outcompete nonenzymatic water addition to
nitroalkene substrates 2a−d, might pose a possible constraint
on the use of our developed chemoenzymatic cascade synthesis
for large scale transformations. To address this issue, we
currently run protein engineering studies with the aim to
further enhance the unnatural “Michaelase” activities of 4 OT
L8Y/M45Y/F50A, which would allow lower catalyst loadings.
While all three steps of the cascade reaction were performed
under aqueous conditions with high conversions, the chemical
reduction step requires 10 equiv of nickel boride and has to be
performed at acidic pH, which is not directly compatible with
the enzymatic steps that require neutral pH. It will be
interesting to investigate whether the chemical reduction step
can be replaced by an enzymatic step, converting the γ-
nitrobutyric acids 4a−d into GABA analogues 5a−d. However,
such an entirely enzymatic cascade route for the straightfor-
ward synthesis of pharmaceutically active GABA analogues
awaits the discovery or engineering of an appropriate
nitroreductase capable of completely reducing the aliphatic
nitro group of 4a−d to the amine group [at the expense of
NAD(P)H] in a controlled and eﬃcient fashion, without
formation of unstable, reactive intermediates that lower the
yield of the desired amino acid product. Although increasingly
investigated, reported nitroreductases prefer nitroaromatic
substrates and often catalyze only partial reduction of nitro
groups to the reactive nitroso or hydroxylamino products.29
We have initiated studies aimed at exploring a large collection
of putative nitroreductases, as well as engineered variants
thereof, for their ability to eﬃciently reduce γ-nitrobutyric
acids 4a−d into γ-aminobutyric acids 5a−d. As such, our work
sets the stage for further development of “artiﬁcial metabo-
lisms” for the greener, more sustainable and step-economic
synthesis of an important class of pharmaceuticals.
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(33) García-García, P.; Ladeṕeĉhe, A.; Halder, R.; List, B. Catalytic
Asymmetric Michael Reactions of acetaldehyde. Angew. Chem., Int. Ed.
2008, 47, 4719−4721.
(34) Hayashi, Y.; Itoh, T.; Ohkubo, M.; Ishikawa, H. Asymmetric
Michael Reaction of Acetaldehyde Catalyzed by Diphenylprolinol
Silyl Ether. Angew. Chem., Int. Ed. 2008, 47, 4722−4724.
ACS Catalysis Research Article
DOI: 10.1021/acscatal.8b04299
ACS Catal. 2019, 9, 1503−1513
1513
